8-K: Aprea Therapeutics Stockholders Affirm Leadership and Governance at 2025 Annual Meeting

Aprea Therapeutics, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all proposed resolutions, including the election of three Class III directors and the ratification of its independent accounting firm, were approved.

Summary

• Aprea Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025.
• Approximately 69.09% of the company's common stock, or 3,817,718 out of 5,525,172 shares, were represented at the meeting, constituting a quorum.
• Stockholders elected Jean-Pierre Bizzari, M.D., Oren Gilad, Ph.D., and John B. Henneman III as Class III directors, each to serve until the 2028 Annual Meeting.
• The appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the 2025 fiscal year was ratified.
• Stockholders approved, by non-binding advisory vote, the compensation of the company's named executive officers.
• Stockholders also approved, by non-binding advisory vote, that the frequency of future votes on the compensation of named executive officers will be every 1 year, with 1,159,068 votes for 1 year, 1,464 for 2 years, and 553,310 for 3 years.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as all proposed resolutions at the annual meeting were approved by stockholders, indicating stable corporate governance and shareholder alignment with management's recommendations.

Positives

• All four proposals submitted to stockholders at the Annual Meeting were approved, indicating strong shareholder support for the company's governance and management.
• The election of all proposed Class III directors (Jean-Pierre Bizzari, M.D., Oren Gilad, Ph.D., and John B. Henneman III) ensures continuity in the board's leadership.
• The ratification of EisnerAmper LLP as the independent auditor for 2025 provides stability in financial oversight.
• The approval of named executive officer compensation by a non-binding advisory vote suggests shareholder confidence in the current compensation structure.
• A high quorum of approximately 69.09% of shares entitled to vote demonstrates significant shareholder engagement.

Future Outlook

The elected Class III directors are expected to hold office until the 2028 Annual Meeting of Stockholders. Future non-binding advisory votes on the compensation of named executive officers will occur annually.

Management Comments

• The report was signed by Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics, Inc.

Industry Context

This 8-K filing details routine corporate governance actions for a publicly traded company, reflecting standard compliance with SEC regulations regarding annual stockholder meetings. The outcomes are typical for companies with stable management and shareholder relations.

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes directly influenced the composition of the board and approved key governance matters, including executive compensation and auditor appointment, indicating their continued support and engagement.
• Management: The approval of executive compensation and the re-election of directors suggest shareholder confidence in the current leadership and strategic direction.

Next Steps

• The elected Class III directors will serve until the 2028 Annual Meeting of Stockholders.
• Future non-binding advisory votes on the compensation of named executive officers will be held annually.

Key Dates

Recommendation

Keywords

Aprea Therapeutics, APRE, SEC Filing, 8-K, Annual Meeting, Stockholders, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, Say-on-Pay, NASDAQ